NF-κB in the crosshairs: Rethinking an old riddle

Jason Bennett, Daria Capece, Federica Begalli, Daniela Verzella, Daniel D'Andrea, Laura Tornatore, Guido Franzoso

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Constitutive NF-κB signalling has been implicated in the pathogenesis of most human malignancies and virtually all non-malignant pathologies. Accordingly, the NF-κB pathway has been aggressively pursued as an attractive therapeutic target for drug discovery. However, the severe on-target toxicities associated with systemic NF-κB inhibition have thus far precluded the development of a clinically useful, NF-κB-targeting medicine as a way to treat patients with either oncological or non-oncological diseases. This minireview discusses some of the more promising approaches currently being developed to circumvent the preclusive safety liabilities of global NF-κB blockade by selectively targeting pathogenic NF-κB signalling in cancer, while preserving the multiple physiological functions of NF-κB in host defence responses and tissue homeostasis.
Original languageEnglish
Pages (from-to)108-112
Number of pages5
JournalInternational Journal of Biochemistry and Cell Biology
Volume95
Early online date23 Dec 2017
DOIs
Publication statusPublished - Feb 2018
Externally publishedYes

Fingerprint

Tissue homeostasis
Pathology
Drug Discovery
Medicine
Toxicity
Neoplasms
Homeostasis
Safety
Therapeutics

Bibliographical note

© 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).

Keywords

  • Cancer
  • NF-κB
  • BIKKβ
  • GADD45β
  • DTP3

Cite this

Bennett, J., Capece, D., Begalli, F., Verzella, D., D'Andrea, D., Tornatore, L., & Franzoso, G. (2018). NF-κB in the crosshairs: Rethinking an old riddle. International Journal of Biochemistry and Cell Biology, 95, 108-112. https://doi.org/10.1016/j.biocel.2017.12.020

NF-κB in the crosshairs: Rethinking an old riddle. / Bennett, Jason; Capece, Daria ; Begalli, Federica; Verzella, Daniela ; D'Andrea, Daniel ; Tornatore, Laura ; Franzoso, Guido .

In: International Journal of Biochemistry and Cell Biology, Vol. 95, 02.2018, p. 108-112.

Research output: Contribution to journalArticle

Bennett, J, Capece, D, Begalli, F, Verzella, D, D'Andrea, D, Tornatore, L & Franzoso, G 2018, 'NF-κB in the crosshairs: Rethinking an old riddle' International Journal of Biochemistry and Cell Biology, vol. 95, pp. 108-112. https://doi.org/10.1016/j.biocel.2017.12.020
Bennett, Jason ; Capece, Daria ; Begalli, Federica ; Verzella, Daniela ; D'Andrea, Daniel ; Tornatore, Laura ; Franzoso, Guido . / NF-κB in the crosshairs: Rethinking an old riddle. In: International Journal of Biochemistry and Cell Biology. 2018 ; Vol. 95. pp. 108-112.
@article{4257ccf29f8f41c6b0c32082d1084fd0,
title = "NF-κB in the crosshairs: Rethinking an old riddle",
abstract = "Constitutive NF-κB signalling has been implicated in the pathogenesis of most human malignancies and virtually all non-malignant pathologies. Accordingly, the NF-κB pathway has been aggressively pursued as an attractive therapeutic target for drug discovery. However, the severe on-target toxicities associated with systemic NF-κB inhibition have thus far precluded the development of a clinically useful, NF-κB-targeting medicine as a way to treat patients with either oncological or non-oncological diseases. This minireview discusses some of the more promising approaches currently being developed to circumvent the preclusive safety liabilities of global NF-κB blockade by selectively targeting pathogenic NF-κB signalling in cancer, while preserving the multiple physiological functions of NF-κB in host defence responses and tissue homeostasis.",
keywords = "Cancer, NF-κB, BIKKβ, GADD45β, DTP3",
author = "Jason Bennett and Daria Capece and Federica Begalli and Daniela Verzella and Daniel D'Andrea and Laura Tornatore and Guido Franzoso",
note = "{\circledC} 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).",
year = "2018",
month = "2",
doi = "10.1016/j.biocel.2017.12.020",
language = "English",
volume = "95",
pages = "108--112",
journal = "International Journal of Biochemistry and Cell Biology",
issn = "1357-2725",
publisher = "Elsevier",

}

TY - JOUR

T1 - NF-κB in the crosshairs: Rethinking an old riddle

AU - Bennett, Jason

AU - Capece, Daria

AU - Begalli, Federica

AU - Verzella, Daniela

AU - D'Andrea, Daniel

AU - Tornatore, Laura

AU - Franzoso, Guido

N1 - © 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).

PY - 2018/2

Y1 - 2018/2

N2 - Constitutive NF-κB signalling has been implicated in the pathogenesis of most human malignancies and virtually all non-malignant pathologies. Accordingly, the NF-κB pathway has been aggressively pursued as an attractive therapeutic target for drug discovery. However, the severe on-target toxicities associated with systemic NF-κB inhibition have thus far precluded the development of a clinically useful, NF-κB-targeting medicine as a way to treat patients with either oncological or non-oncological diseases. This minireview discusses some of the more promising approaches currently being developed to circumvent the preclusive safety liabilities of global NF-κB blockade by selectively targeting pathogenic NF-κB signalling in cancer, while preserving the multiple physiological functions of NF-κB in host defence responses and tissue homeostasis.

AB - Constitutive NF-κB signalling has been implicated in the pathogenesis of most human malignancies and virtually all non-malignant pathologies. Accordingly, the NF-κB pathway has been aggressively pursued as an attractive therapeutic target for drug discovery. However, the severe on-target toxicities associated with systemic NF-κB inhibition have thus far precluded the development of a clinically useful, NF-κB-targeting medicine as a way to treat patients with either oncological or non-oncological diseases. This minireview discusses some of the more promising approaches currently being developed to circumvent the preclusive safety liabilities of global NF-κB blockade by selectively targeting pathogenic NF-κB signalling in cancer, while preserving the multiple physiological functions of NF-κB in host defence responses and tissue homeostasis.

KW - Cancer

KW - NF-κB

KW - BIKKβ

KW - GADD45β

KW - DTP3

U2 - 10.1016/j.biocel.2017.12.020

DO - 10.1016/j.biocel.2017.12.020

M3 - Article

VL - 95

SP - 108

EP - 112

JO - International Journal of Biochemistry and Cell Biology

JF - International Journal of Biochemistry and Cell Biology

SN - 1357-2725

ER -